Clinical Trials Directory

Trials / Completed

CompletedNCT05935501

Clinical Trial of Cross-linked Hyaluronic Acid Dermal Filler

Safety and Efficacy of Formaderm Young Dermal Filler Injection for the Correction of Moderate-to-severe Facial Wrinkles.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
320 (actual)
Sponsor
Maxigen Biotech Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of Formaderm Young Dermal Filler Injection, which is a hyaluronic acid dermal filler injected into the mid to deep dermis for the correction of moderate-to-severe nasolabial fold facial wrinkles. The main questions it aims to answer are: * The differences of Wrinkle Severity Rating Scale (WSRS) after the injection. * The treatment improvement assessed by Global Aesthetic Improvement Scale (GAIS). * Safety Indicators of which incidences on the day of the injection or after the injection. Participants will be blinded and randomized into either experiment group or control group, and re-visited on 1, 3, 6, 9 and 12 month after injection. Researchers will compare if the test product is non-inferiority to Restylane.

Detailed description

A prospective, parallel, two-center, non-inferior, randomized, double-blind trial was conducted in this study. It was planned to recruit 157 subjects for each group, considering a 10% dropout rate that would lead to 320 subjects overall. Subjects eligible in the screening will be enrolled. Each patient will receive the same treatment, either Formaderm Young Dermal Filler Injection or Restylane, to correct both sides of the nasolabial fold through randomization. Clinical efficacy will be assessed by the blinded physician using the WSRS and GAIS, as well as by subjects using GAIS. The safety issue of Formaderm Young or Restylane will be identified and recorded during the course of the study.

Conditions

Interventions

TypeNameDescription
DEVICEFormaderm YoungDermal filler injection to facial areas.
DEVICERestylaneDermal filler injection to facial areas.

Timeline

Start date
2018-08-27
Primary completion
2021-10-20
Completion
2023-04-06
First posted
2023-07-07
Last updated
2023-07-07

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05935501. Inclusion in this directory is not an endorsement.